Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    RENAL CANCER E7080
Show Display Options
RSS Create an RSS feed from your search for:
RENAL CANCER E7080
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Lenvatinib;   Drug: Everolimus
2 Recruiting Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: lenvatinib;   Drug: everolimus;   Drug: pembrolizumab;   Drug: Sunitinib
3 Not yet recruiting A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Condition: Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions: Drug: lenvatinib;   Drug: everolimus
4 Active, not recruiting Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Lenvatinib;   Drug: Everolimus
5 Recruiting Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Condition: Tumors
Interventions: Drug: Lenvatinib;   Drug: Pembrolizumab
6 Completed A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
Conditions: Advanced Solid Tumors;   Lymphomas
Intervention: Drug: Lenvatinib
7 Active, not recruiting
Has Results
An Open Label Phase I Dose Escalation Study Of E7080
Condition: Solid Tumor or Lymphoma
Intervention: Drug: Lenvatinib

Study has passed its completion date and status has not been verified in more than two years.